Ignite Creation Date:
2025-12-24 @ 10:43 PM
Ignite Modification Date:
2026-01-02 @ 11:26 PM
Study NCT ID:
NCT03905135
Status:
COMPLETED
Last Update Posted:
2022-09-13
First Post:
2019-04-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-07
Start Date Type:
ACTUAL
Primary Completion Date:
2021-03-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-05-17
Completion Date Type:
ACTUAL
First Submit Date:
2019-04-03
First Submit QC Date:
None
Study First Post Date:
2019-04-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-03-22
Results First Submit QC Date:
None
Results First Post Date:
2022-09-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-16
Last Update Post Date:
2022-09-13
Last Update Post Date Type:
ACTUAL